-
Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (SVNT)
Monday, May 2, 2011 - 8:16am | 114Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it has granted time-based and performance-based options to purchase shares of common stock to Richard Crowley, the Company's newly appointed Executive Vice President of Biopharmaceutical Operations. The grants were made pursuant to...
-
Keryx Biopharmaceuticals Receives Positive Scientific Advice from the European Medicines Agency for Zerenex in Hyperphosphatemia
Monday, May 2, 2011 - 8:15am | 133Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), announced today that it has received positive Scientific Advice from the European Medicines Agency for the development of Zerenex for the management and control of serum phosphorus in end-stage renal disease patients undergoing dialysis, and in pre-...
-
Benzinga's Top Pre-Market NASDAQ Gainers (TIVO, SPPI, CEPH, TLCR)
Monday, May 2, 2011 - 8:13am | 165TiVo Inc (NASDAQ: TIVO) shares surged 17.76% to $11.27 in the pre-market session. Dish Network (NASDAQ: DISH) and EchoStar (NASDAQ: SATS) will pay $500 million to TiVo in settlement over DVR technology. Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) shares advanced 16.67% to $10.50 in the pre-market...
-
Biotechnology Outperforms YTD, Goldman Sachs Reports (BIIB)
Monday, May 2, 2011 - 8:01am | 96“The outperformance has largely been led by the SMIDs, which in our coverage are up 45% YTD vs. 11% for large caps (and 4% excluding outlier Biogen Idec Inc. (NASDAQ: BIIB)), where the new product story has increasingly become better and has the potential to drive sustainable growth bringing...
-
J.P. Morgan Maintains Neutral on Vertex Pharmaceuticals (VRTX)
Monday, May 2, 2011 - 7:57am | 127J.P. Morgan is out with its report today on Vertex Pharmaceuticals (NASDAQ: VRTX), maintaining Neutral. In a note to clients, J.P. Morgan writes, "We remain very impressed by VX-770 in the G551D CF population and together with Class 4/5 CF patients, we estimate a peak opportunity approaching $1B...
-
Targacept to Retain Full Rights for TC-5619
Monday, May 2, 2011 - 7:55am | 45Targacept, Inc. (NASDAQ: TRGT) today announced that AstraZeneca will not exercise its option to license Targacept's product candidate TC-5619. As a result, Targacept retains full rights to the compound, a highly selective alpha7 neuronal nicotinic receptor modulator.
-
UPDATE: TEVA To Buy Cephalon for $6.8 billion; Shares Rise In Pre-Market Trading
Monday, May 2, 2011 - 7:50am | 85Shares of Cephalon Inc (NASDAQ: CEPH) and Teva Pharmaceutical Industries (NASDAQ: TEVA) gained in pre-market trading after TEVA agreed to purchase Cephalon for $6.8 billion. Teva's cash offer of $81.50 per share represents a 6% premium over Cephalon closing price on Friday. CEPH shares gained 6....
-
Seattle Genetics Announces FDA Accepts Brentuximab Vedotin BLAs for Filing and Grants Review for Hodgkin Lymphoma and Systemic ALCL (SGEN)
Monday, May 2, 2011 - 7:40am | 148Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration has accepted for filing two Biologics License Applications for brentuximab vedotin, including one for the treatment of patients with relapsed or refractory Hodgkin lymphoma and one for the treatment of...
-
Piper Jaffray Reiterates Overeweight on Regeneron Pharmaceuticals (REGN)
Monday, May 2, 2011 - 7:30am | 145Piper Jaffray is out with its report today on Regeneron Pharmaceuticals (NASDAQ: REGN), reiterating Overweight. In a note to clients, Piper Jaffray writes, "We are attending ARVO where CATT was enthusiastically received. Feedback was that the data were as expected proving Avastin to be equivalent...
-
Teva Acquires Cephalon for $81.50 (TEVA, CEPH)
Monday, May 2, 2011 - 7:07am | 512Teva Pharmaceutical Industries (NASDAQ: TEVA) and Cephalon (NASDAQ: CEPH) today announced that their Boards of Directors have unanimously approved a definitive agreement under which Teva will acquire all of the outstanding shares of Cephalon for $81.50 per share in cash, or a total enterprise value...
-
Cephalon Acquired by Teva for $81.50/Share Cash (CEPH, TEVA)
Monday, May 2, 2011 - 7:05am | 27Cephalon (NASDAQ: CEPH) Acquired by Teva (NASDAQ: TEVA) for $81.50/Share Cash.
-
TOP 15 Stocks To Watch this week- AAPL, BRK-A, BRK-B, BJ, C, F, GM, GPRO, IP, KND, N, NRTLQ, ONTY, SPPI, YRCW
Monday, May 2, 2011 - 4:48am | 2069Ford (NYSE:F)- Ford revenue increased 17% from last year to $33.1 billion and reduced its debt by $2.5 billion. The result showed an increase of $466 million over the first quarter of 2010, and is the best first quarter earnings since 1998. Competitors- General Motors Company (GM), Toyota Motor...
-
CEOWORLD Top 5 Analyst Calls of the Week- DNDN, INSP, MCP, SIRI, VICL
Monday, May 2, 2011 - 3:32am | 1198Dendreon Corporation (NASDAQ: DNDN)- Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. The Company's product portfolio includes active cellular...
-
Key earnings announcements for this week ADM, PFI, K, GM- CMCSA, WFMI, CVS, V, ED
Monday, May 2, 2011 - 3:13am | 866May 3, 2011: Archer Daniels Midland Company (NYSE:ADM) and Pfizer (NYSE:PFI) before the opening Bell, and after the close, Comcast (NASDAQ:CMCSA) reports. May 4, 2011: Kellogg (NYSE:K) reports before the opening Bell, and Whole Foods (NASDAQ:WFMI) reports after the close. May 5, 2011: CVS (NYSE:...
-
Stem Cell Funding Band Reversed: What About the Stocks?
Sunday, May 1, 2011 - 6:14pm | 622Last week was a busy week for stem cells. The suspension of Federal funding for stem cell research has just been overturned by a United States Appeals Court. The two to one ruling last week said that the law against Federal funding was ambiguous. In addition, Dr. Paul Sharpe spoke at the First...